(0.25%) 5 321.41 points
(0.17%) 39 873 points
(0.22%) 16 833 points
(-0.25%) $79.06
(-0.26%) $2.66
(-0.02%) $2 425.30
(0.63%) $32.28
(0.09%) $1 061.90
(0.04%) $0.921
(-0.27%) $10.67
(-0.04%) $0.787
(-0.20%) $90.49
@ $0.657
発行日: 15 2月 2024 @ 05:30
リターン: 181.80%
前回のシグナル: 2月 14 - 23:30
前回のシグナル:
リターン: 6.16 %
Live Chart Being Loaded With Signals
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD...
Stats | |
---|---|
本日の出来高 | 6.63M |
平均出来高 | 9.47M |
時価総額 | 476.06M |
EPS | $0 ( 2024-05-14 ) |
次の収益日 | ( $-0.0600 ) 2024-08-19 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.04 |
ATR14 | $0.00700 (0.38%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Qamar Huma | Buy | 308 465 | Option (Right to Buy) |
2024-03-18 | Qamar Huma | Sell | 0 | Common Stock |
2023-09-15 | Breininger Michael | Buy | 0 | |
2024-01-03 | Musunuri Shankar | Sell | 180 204 | Common Stock |
2024-01-03 | Upadhyay Arun | Sell | 41 633 | Common Stock |
INSIDER POWER |
---|
65.74 |
Last 96 transactions |
Buy: 10 862 012 | Sell: 2 992 475 |
ボリューム 相関
Ocugen Inc 相関
10 最も負の相関 | |
---|---|
UONEK | -0.918 |
RMGC | -0.904 |
PRTS | -0.902 |
TTEC | -0.902 |
ACAD | -0.9 |
UONE | -0.897 |
AGRX | -0.895 |
EEIQ | -0.895 |
NLSP | -0.893 |
QNRX | -0.892 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Ocugen Inc 相関 - 通貨/商品
Ocugen Inc 財務諸表
Annual | 2023 |
収益: | $6.04M |
総利益: | $5.33M (88.34 %) |
EPS: | $-0.260 |
FY | 2023 |
収益: | $6.04M |
総利益: | $5.33M (88.34 %) |
EPS: | $-0.260 |
FY | 2022 |
収益: | $0 |
総利益: | $-1.07M (0.00 %) |
EPS: | $-0.360 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.300 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。